Loading...
XKRX008930
Market cap1.35bUSD
Dec 24, Last price  
29,050.00KRW
1D
-0.34%
1Q
-11.70%
Jan 2017
-52.45%
Name

Hanmi Science Co Ltd

Chart & Performance

D1W1MN
XKRX:008930 chart
P/E
17.09
P/S
1.58
EPS
1,700.12
Div Yield, %
0.68%
Shrs. gr., 5y
-0.21%
Rev. gr., 5y
12.00%
Revenues
1.25t
+19.30%
531,396,197,000606,802,686,000689,962,982,000641,470,958,00016,812,302,74019,645,989,150219,862,566,010532,604,690,900776,215,271,160665,284,666,050652,324,367,920707,995,356,120816,618,823,610857,383,419,140950,164,817,3401,046,054,210,8301,247,906,379,060
Net income
115.12b
+66.34%
52,997,718,00071,551,234,00050,526,894,0005,977,013,000-14,690,506,00012,479,133,0009,578,328,00021,312,164,080178,520,883,2207,937,683,00030,068,972,51018,019,525,57030,741,649,30022,601,096,23042,941,995,98069,209,578,700115,121,512,760
CFO
35.16b
+271.98%
-16,175,604,00040,923,068,00060,933,793,00036,493,513,000-7,675,597,550-175,636,290-234,788,3005,245,497,90046,927,261,70076,523,442,300-33,681,816,8402,701,370,43013,024,009,77013,817,514,74013,689,812,1009,451,693,03035,158,260,380
Dividend
Jun 27, 2024100 KRW/sh
Earnings
Jan 31, 2025

Profile

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.
URL
http://www.hanmiscience.co.kr/
IPO date
Jun 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,247,906,379
19.30%
1,046,054,211
10.09%
950,164,817
10.82%
Cost of revenue
1,089,168,310
1,899,347,870
870,105,155
Unusual Expense (Income)
NOPBT
158,738,069
(853,293,659)
80,059,663
NOPBT Margin
12.72%
8.43%
Operating Taxes
15,421,789
4,144,397
6,182,265
Tax Rate
9.72%
7.72%
NOPAT
143,316,281
(857,438,057)
73,877,398
Net income
115,121,513
66.34%
69,209,579
61.17%
42,941,996
90.00%
Dividends
(13,332,560)
(13,190,733)
(12,934,622)
Dividend yield
0.50%
0.59%
0.35%
Proceeds from repurchase of equity
(7,825,448)
(622,622)
(6,014,346)
BB yield
0.29%
0.03%
0.16%
Debt
Debt current
202,967,456
195,520,257
56,293,127
Long-term debt
12,146,099
8,809,483
1,695,593
Deferred revenue
2,932,623
8,303,588
14,358,505
Other long-term liabilities
17,311,773
16,594,044
23,758,518
Net debt
(555,865,547)
(521,522,289)
(612,391,121)
Cash flow
Cash from operating activities
35,158,260
9,451,693
13,689,812
CAPEX
(8,769,107)
(8,342,387)
(2,214,500)
Cash from investing activities
(18,675,117)
(2,134,913)
(2,153,982)
Cash from financing activities
(10,227,974)
(1,076,010)
(11,016,774)
FCF
157,093,509
(950,714,016)
58,988,833
Balance
Cash
33,578,959
21,513,397
16,629,592
Long term investments
737,400,143
704,338,632
653,750,248
Excess cash
708,583,783
673,549,318
622,871,600
Stockholders' equity
317,533,413
655,112,390
606,881,830
Invested Capital
703,919,526
291,340,276
171,357,849
ROIC
28.80%
44.07%
ROCE
15.35%
10.28%
EV
Common stock shares outstanding
67,956
68,494
68,619
Price
39,200.00
20.80%
32,450.00
-38.93%
53,137.25
-27.35%
Market cap
2,663,867,713
19.85%
2,222,629,229
-39.04%
3,646,236,807
-27.37%
EV
2,107,967,684
1,701,108,717
3,033,842,378
EBITDA
167,470,449
(847,815,212)
85,316,205
EV/EBITDA
12.59
35.56
Interest
10,160,601
3,689,325
1,794,046
Interest/NOPBT
6.40%
2.24%